A detailed history of Geode Capital Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 974,967 shares of ACLX stock, worth $97.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
974,967
Previous 935,186 4.25%
Holding current value
$97.8 Million
Previous $51.6 Million 57.75%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$50.91 - $86.61 $2.03 Million - $3.45 Million
39,781 Added 4.25%
974,967 $81.4 Million
Q2 2024

Aug 09, 2024

BUY
$49.74 - $66.98 $4.81 Million - $6.48 Million
96,717 Added 11.53%
935,186 $51.6 Million
Q1 2024

May 13, 2024

BUY
$51.85 - $73.49 $2.75 Million - $3.9 Million
53,067 Added 6.76%
838,469 $58.3 Million
Q4 2023

Feb 13, 2024

BUY
$31.75 - $57.99 $1.47 Million - $2.69 Million
46,348 Added 6.27%
785,402 $43.6 Million
Q3 2023

Nov 13, 2023

BUY
$31.51 - $37.4 $1.7 Million - $2.01 Million
53,826 Added 7.86%
739,054 $26.5 Million
Q2 2023

Aug 11, 2023

BUY
$27.49 - $46.9 $3.4 Million - $5.8 Million
123,624 Added 22.01%
685,228 $21.7 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $453,171 - $571,345
16,834 Added 3.09%
561,604 $17.3 Million
Q4 2022

Feb 13, 2023

BUY
$17.18 - $33.0 $346,640 - $665,841
20,177 Added 3.85%
544,770 $16.9 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $5.56 Million - $7.35 Million
333,285 Added 174.21%
524,593 $9.85 Million
Q2 2022

Aug 12, 2022

BUY
$7.21 - $24.43 $364,523 - $1.24 Million
50,558 Added 35.92%
191,308 $3.46 Million
Q1 2022

May 13, 2022

BUY
$12.97 - $19.14 $1.83 Million - $2.69 Million
140,750 New
140,750 $1.97 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $4.4B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.